Uncategorized

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation will be presented at the 65th American Society of Hematology Annual Meeting held from December 9-12, 2023, in San Diego, California, USA.

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced the construction of its new Good Manufacturing Practices compliant manufacturing facility in Gembloux, Belgium, for radiopharmaceuticals.

Though only a quarter of respondents said they’d already adopted the tools, 58% reported they were likely to do so within the next year, according to Klas Research.

The data highlights how convenient access to abortion care has been eliminated in many states after the fall of Roe v. Wade last summer. 

The company plans to make the device available in Western Europe this month and “launch in additional regions based on local regulations.”

The Great Lakes state will issue harsher penalties next year in an attempt to deter workplace assault and harassment.

The agency’s plans include working with Congress to receive funding to support hospitals’ security infrastructures as the sector faces the growing threat of cyberattacks.

Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.

The White House is supporting a policy that would allow the U.S. government to sidestep patent protections for drugs developed with federal funding and that have prices deemed “extreme, unjustified, and exploitative.”

For the medtech industry overall, the analysts wrote that procedure volume growth is likely to normalize after declining due to the COVID-19 pandemic.